I hereby certify that on CERTIFIC TE OF MAILING

this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IW

127 C.F.R. § 1.8(a) 37 C.F.R. § 1.10

with safficient postage as Expres

Express Mail Post Office to Addressee

**Attorney Docket No.:** PA917 (51288-00053)

9953

3763

Unknown

Conf. No.:

Examiner:

Art Unit:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Richard Thomas

Serial No.:

10/749,186

Filed:

December 30, 2003

Title:

MEDICAL DEVICES HAVING DRUG

RELEASING POLYMER RESERVOIRS

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56. 1.97 AND 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. §§ 1.56. 1.97 and 1.98, and in accordance with the provisions in the Manual of Patent Examining Procedure §§609 and 707.05(b), enclosed is FORM PTO-1449 listing the references that are known to applicant. Copies of each of the Non-US patent references listed are enclosed.

This Information Disclosure Statement is being timely filed under 37 C.F.R. § 1.97(b)(3), before the mailing of a first Office Action on the Merits.

The submission of the above-described documents does not constitute an admission that any of them are valid prior art against the claims of the present application. That is, applicant reserves the right to antedate or otherwise remove the documents as references.

It is respectfully requested that the listed references be considered in the examination of this application and identified on the list of references cited on the patent issuing for this application. Applicant also requests that an initialed copy of FORM PTO-1449 be entered in the application file and returned to applicant with the next communication from the Office in accordance with MPEP § 609.

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application. The Director is hereby

Information Disclosure Statement Application Serial No. 10/749,186 Page 2 of 2 PATENT Attorney Docket No.: PA917 (51288-00053)

authorized to charge any fees or credit any overpayments to Deposit Account No. 50-3207 associated with this response.

Respectfully submitted,

PRESTON GATES & ELLIS, LLP

LOUIS CULLMAN
Attorney for Applicant

Registration No. 39,645

Date

9/24/01

Contact information below for inquiries regarding the above submission:

Customer No.: 28,390 Louis C. Cullman Preston Gates Ellis LLP (949) 253-0900 Telephone (949) 253-0902 Fax

Enclosures: PTO-1440 and Non-US patent References cited thereon, Transmittal.

### FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Attorney Docket Number	PA917 (51288-00053)
Application Number	10/749,186
Filing Date	December 30, 2003
Applicant(s)	Richard Thomas
Group Art Unit	3763
Examiner Name	Unknown

		U.S. PA	TENT DOCUMENTS			
EXAMINER	DOCUMENT	ISSUE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
INITIALS	NUMBER 4 272 000	DATE 02/08/83	Winn	428	424.2	II ATROTRIATE
	4,373,009	04/29/86	Lambert	427	2	
OIPE	4,585,666	11/25/86	Rizk et al.	528	28	
0.76	4,625,012		Moreau et al.	424	426	
<b>18</b>	4,894,231	01/16/90		528	70	
2 7 2004	5,032,666	07/16/91	Hu et al.	607	122	
#GZ	5,040,544	08/20/91	Lessar et al.			
O SMARK OF	5,104,404	04/14/92	Wolff	623	1.16	· · · · · · · · · · · · · · · · · · ·
105MABK	5,134,192	07/28/92	Feijen et al.	525	54.1	
	5,171,217	12/15/91	March et al.	604	507	
	5,342,621	08/30/94	Eury	424	423	
	5,380,299	01/10/95	Fearnot et al.	604	265	
	5,380,299	01/10/95	Fearnot et al.	604	265	<u> </u>
	5,383,928	01/24/95	Scott et al.	623	1.12	
	5,443,458	08/22/95	Eury	604	891.1	
	5,447,724	09/05/95	Heimus et al.	424	426	
	5,464,450	11/07/95	Buscemi et al.	623	1.2	
	5,464,650	11/07/95	Berg et al.	427	2.3	·
	5,464,650	11/07/95	Berg et al.	427	2.3	
	5,470,307	11/28/95	Lindall	604	20	
	5,510,077	. 04/23/96	Dinh et al.	264	485	
	5,512,055	04/30/96	Domb et al.	604	265	
	5,525,348	06/11/96	Whitbourne et al.	424	423	
	5,545,208	08/13/96	Wolff et al.	623	1.22	
	5,551,954	09/03/96	Buscemi et al.	623	1.15	
	5,554,182	09/10/96	Dinh et al.	600	36	
<del> </del>	5,554,182	09/10/96	Binh et al.	600	36	
	5,562,922	10/08/96	Lambert	424	486	
	5,571,089	11/05/96	Crocker	604	103.01	
<del>                                     </del>	5,571,166	11/05/96	Dinh et al.	128	898	
	5,591,197	01/07/97	Orth et al.	623	1.16	Y
	5,591,197	01/07/97	Dinh et al.	623	1.22	
<b>—</b>	5,591,277	01/07/97	Braunhein	148	578	
		02/04/97	Dinh et al.	128	898	
	5,599,352		Eury et al.	424	423	
	5,605,696	02/25/97		424	423	
<u> </u>	5,605,696	02/25/97	Eury et al.	424	423	<del> </del>
	5,605,696	02/25/97	Eury et al.	424	1 423	<u>l,                                      </u>

EXAMINER	DATE	
SIGNATURE	CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is i	in conformance with MPEP 609; Draw	line through citation if not in conformance and not
considered. Include copy of this form with next communication to appl	licant.	

# FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

<b>Attorney Docket Number</b>	PA917 (51288-00053)
Application Number	10/749,186
Filing Date	December 30, 2003
Applicant(s)	Richard Thomas
Group Art Unit	3763
Examiner Name	Unknown

	5,609,629	03/11/97	Fearnot et al.	623	1.42	
	5,612,052	03/18/97	Shalaby	424	426	
	5,624,411	04/29/97	Tuch	604	265	
	5,637,113	06/10/97	Tartaglia et al.	623	1.42	
	5,645,931	07/08/97	Fan et al.	428	334	
	5,660,873	08/26/97	Nikolaychik et al.	427 ·	2.24	
	5,662,960	09/02/97	Hostettler et al.	427	2.3	
	5,674,192	10/07/97	Sahatjian et al.	604	28	
	5,679,400	10/21/97	Tuch	427	2.14	
	5,679,659	10/21/97	Verhoeven et al.	514	56	
	5,683,451	11/04/97	Lenker et al.	623	1.11	
<u> </u>	5,697,967	12/16/97	Dinh et al.	120	898	
	5,698,738	12/16/97	Garfield et al.	564	112	
	5,700,286	12/23/97	Tartaglia et al.	623	1.15	
	5,700,286	12/23/97	Tartaglia et al.	623	1.15	
	5,702,754	12/30/97	Zhong	427	2.12	
	5,705,583	01/06/98	Bowers et al.	526	277	
	5,756,145	05/26/98	Darouiche	427	2.24	
	5,756,553	05/26/98	Iguchi et al.	514	772.3	
	5,762,944	06/09/98	Inoue et al.	424	400	
	5,770,229	06/23/98	Tanihara et al.	424	488	
	5,776,184	07/07/98	Tuch	623	1.11	
	5,776,611	07/07/98	Elton et al.	428	423.1	
	5,792,106	08/11/98	Mische	604	103.01	
	5,797,887	08/25/98	Rosen et al.	604	265	
	5,811,447	09/22/98	Kunz et al.	514	411	
	5,820,917	10/13/98	Tuch et al.	427	2.1	
	5,824,049	10/20/98	Ragheb et al.	623	1.44	
	5,824,054	10/20/98	Khosravi et al.	623	1.44	
	5,837,008	11/17/98	Berg et al.	128	898	
	5,837,313	11/17/98	Dinh et al.	427	2.21	
	5,843,120	12/01/98	Israel et al.	523	1.15	
	5,843,166	12/01/98	Lentz et al.	623	1.13	
	5,843,172	12/01/98	Yan	623	1.42	
-	5,849,368	12/15/98	Hostettler et al.	427	536	
	5,851,217	12/22/98	Wolff et al.	606	191	
	5,851,231	12/22/98	Wolff et al.	623	1.42	
	5,853,745	12/29/98	Darouiche	424	423	<u> </u>

EXAMINER	DATE	
SIGNATURE	CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation	is in conformance with MPEP 609; Draw li	ne through citation if not in conformance and not
considered. Include copy of this form with next communication to a	applicant.	

FORM PTO-1449	Attorney Docket Number	PA917 (51288-00053)
INFORMATION DISCLOSURE	Application Number	10/749,186
STATEMENT BY APPLICANT	Filing Date .	December 30, 2003
DIMIDIMINI DI INI DIGINA	Applicant(s)	Richard Thomas
(use as many sheets as necessary)	Group Art Unit	3763
	Examiner Name	Unknown

						· · · · · · · · · · · · · · · · · · ·
	5,865,814	02/02/99	Tuch	623	1.15	
	5,869,127	02/09/99	Zhong	427	2.12	
	5,871,535	02/16/99	Wolff et al.	128	898	
	5,873,904	02/23/99	Ragheb et al.	623	1.13	
	5,891,108	04/06/99	Leone et al.	604	264	
	5,900,246	05/04/99	Lambert	424	429	
	5,919,570	07/06/99	Hostettler et al.	428	424.8	
	5,972,027	10/26/99	Johnson	623	1.42	
	5,997,468	12/07/99	Wolff et al.	600	36	
	5,997,517	12/07/99	Whitebourne	604	265	
	6,004,346	12/21/99	Wolff et al.	623	23.71	
	6,024,763	02/15/00	Lenker et al.	606	191	
	6,048,360	04/11/00	Khosravi et al.	623	1.11	
	6,090,901	07/18/00	Bowers et al.	526	277	
	6,096,070	08/01/00	Ragheb et al.	623	1.39	
	6,153,252	11/28/00	Hossainy et al.	427	2.3	
	6,156,345	12/05/00	Chudzik et al.	424	485	
	6,197,051	03/06/01	Zhong	623	1.46	
	6,214,901	04/10/01	Chudzik et al.	523	113	
	6,254,632	07/03/01	Wu et al.	623	1.15	
	6,258,121	07/10/01	Yang et al.	623	1.46	
	6,273,913	08/14/01	Wright et al.	623	1.42	
	6,287,285	09/11/01	Michal et al.	604	264	
	6,287,628	09/11/01	Hossainy et al.	427	2.3	
	6,299,604	10/09/01	Ragheb et al.	604	265	
	6,306,176	10/23/01	Whitbourne	623	23.59	
	6,344,035	02/05/02	Chudzik et al.	604	265	
	6,355,060	03/12/02	Lenker et al.	623	1.34	
	6,369,039	08/09/02	Palasis et al.	514	44	
	6,379,382	04/30/02	Yang	623	1.42	
	6,451,050	09/17/02	Rudakov et al.	623	1.15	
	6,451,373	09/17/02	Hossainy et al.	427	2.25	
	6,458,152	10/01/02	Khosravi et al.	623	1.13	
	6,488,701	12/03/02	Nolting et al.	623	1.13	
	6,506,437	01/14/03	Harish et al.	427	2.25	
	6,547,814	04/15/03	Edwin et al.	623	1.13	
	6,569,195	05/27/03	Yang et al.	623	1.46	
<del></del>	6,585,764	07/01/03	Wright et al.	623	1.42	

EXAMINER	DATE	
SIGNATURE	CONSIDERED	<u> </u>
EXAMINER: Initial if reference considered, whether or not citation is in conformation	ance with MPEP 609; Draw I	ine through citation if not in conformance and not
considered, Include copy of this form with next communication to applicant.		

### FORM PTO-1449

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Attorney Docket Number	PA917 (51288-00053)
Application Number	10/749,186
Filing Date	December 30, 2003
Applicant(s)	Richard Thomas
Group Art Unit	3763
Examiner Name	Unknown

6,776,796	08/17/04	Folotico et al.	623	1.46	
-----------	----------	-----------------	-----	------	--

FOREIGN PATENT DOCUMENTS								
EXAMINER	DOCUMENT	PUBLICATION	COUNTRY OR	CLASS	SUBCLASS	TRANS YES	LATION NO	
INITIALS	NUMBER	DATE	PATENT OFFICE	CLASS	SUBCLASS	YES.	NU	
	357401B1	3/90	EP					
	352295 B1	6/93	EP					
	397784 B1	10/93	EP					
	0950386A2	10/20/99	EP					
	WO01/67991	9/20/01	PCT				<u>                                     </u>	

	OTHER DOCUMENTS
EXAMINER INITIALS	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Adams et al., "Inhibition of Nitric Oxide Synthase Disrupts Inhibitory Gating of Auditory Responses in Rat Hippocampus," The Journal of Pharmacology and Experimental Therapeutics, 287:760-5 (November 1998)
	Berkenbosch et al., "Management of Postoperative Chylothorax with Nitric Oxide: A Case Report," Critical Care Medicine, 27:1022-4 (May 1999)
	Carrier et al., "Nitric Oxide Inhalation in the Treatment of Primary Graft Failure Following Heart Transplantation," The Journal of Heart and Lung Transplantation, 18:664-7 (July 1999)
	Cooper et al., "Transient Loss of Resistance to Pulmonary Tuberculosis in p47PHOX-/-Mice," Infection and Immunity, 68:1231-4 (March 2000)
	El-Haddad et al., "Nitric Oxide Modulates Spontaneous Swallowing Behaviour in Near-Term Ovine Fetus," American Journal of Physiology, 277:R981-6 (October 1999)
-	Freedman, et al., "Acute Effect of Nitric Oxide on Raynaud's Phenomenon in Scleroderma," The Lancet, 354:739 (August 1999)
	Goodwin et al., "Favorable Response of Eisenmenger Syndrome to Inhaled Nitric Oxide During Pregnancy," American Journal of Obstetrics and Gynecology, 180:64-7 (January 1999)
	Gradini et al., "Nitric Oxide Synthases in Normal and Benign Hyperplastic Human Prostate: Immunohistochemistry and Molecular Biology," Journal of Pathology, 189:224-9 (October 1999)
	Holopainen et al., "Nitric Oxide Inhalation Inhibits Pulmonary Apoptosis but not Inflammatory Injury in Porcine Meconium Aspiration," Acta Paediatrica, 88:1147-55 (October 1999)
	Ishihara et al., "Inhaled Nitric Oxide Prevents Left Ventricular Impairment During Endotoxemia," Journal of Applied Physiology, 85:2018-24 (December 1998)
	Jacobs et al., "Aerosolized Soluble Nitric Oxide Donor Improves Oxygenation and Pulmonary Hypertension in Acute Lung Injury," American Journal of Respiratory and Critical Care Medicine, 158:1536-42 (November 1998)

EXAMINER	DATE	j	
SIGNATURE	CONSIDERED		
EXAMINER: In	itial if reference considered, whether or not citation is in conformance with MPEP 609; Dra	w line through citation if not in conformance and not	
considered, Include copy of this form with next communication to applicant.			

FORM PTO-1449	Attorney Docket Number	PA917 (51288-00053)
	Application Number	10/749,186
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	December 30, 2003
STATEMENT BY APPLICANT	Applicant(s)	Richard Thomas
(use as many sheets as necessary)	Group Art Unit	3763
	Examiner Name	Unknown

	Kiris et al., "Reversal of Cerebral Vasospasm by the Nitric Oxide Donor SNAP in an Experimental Model of Subarachnoid Haemorrhage," Acta Neurochirurgica, 141:1323-9 (1999)
	Lambermont et al., "Effects of Inhaled Nitric Oxide on Pulmonary Hemodynamics in a Porcine Model of Endotoxin Shock," Critical Care Medicine, 27:1953-7 (September 1999)
	Lewis et al., "Nitric Acid Limits the Eicosanoid-Dependant Bronchoconstriction and Hypotension Induced By Endothelin-1 in the Guinea Pig," British Journal of Pharmacology, 126:93-102 (January 1999)
	Payen, et al., "Inhaled Nitric Oxide, Almitrine Infusion, or Their Coadministration as a Treatment of Severe Hypoxemic Focal Lung Lesions," Anesthesiology, 89:1157-65 (November 1998)
	Samama et al., "Inhibition of Nitric Oxide Synthase Impairs Early Olfactory Associative Learning in Newborn Rats." Neurobiology of Learning and Memory, 71:219-31 (March 1999)
1-	Sullivan et al., "Nitric Oxide Successfully used to treat Acute Chest Syndrome of Sickle Cell Disease in a Young Adolescent," Critical Care Medicine, 27:2563-8 (November 1999)

EXAMINER DATE	
SIGNATURE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and no	
considered, Include copy of this form with next communication to applicant.	

PTO/SB/21 (02-04		PT	O/SB/21	(02-04
------------------	--	----	---------	--------

mak H		U.S. Pater	PTO/SB/21 (۱۵2-۵۶ Approved for use through 07/31/2006. OMB 0651-003 at and Trademark Office; U.S. DEPARTMENT OF COMMERC
Under the Paperwork Reduction Act of 1995	no oersons	are required to respond to a collection Application Number	on of information unless it displays a valid OMB control numbe
TRANSMITTAL		Filing Date	December 30, 2003
FORM		First Named Inventor	Richard Thomas
(to be used for all correspondence after initial t	īling)	Art Unit	3763
		Examiner Name	Unknown
Total Number of Pages in This Submission		Attorney Docket Number	PA917 (51288-00053)
	ENCI	OSURES (Check all that	t apply)
Fee Transmittal Form  Fee Attached  Amendment/Reply  After Final  After Final  After Final  After Final  After Attached  Extension of Time Request  Information Disclosure Statement  Certified Copy of Priority  Drawing(s)  Drawing(s)  Licensing-related Papers  Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  Petition  Petition  Petition to Convert to a Provisional Application  Power of Attorney, Revocation Change of Correspondence Address  Terminal Disclaimer  Request for Refund  CD, Number of CD(s)  Response to Missing Parts/ Incomplete Application  Provisional Application  Proprietary Information  Status Letter  Other Enclosure(s) (please Identify below):  PTO-1449 and all non-US references cited thereon.			
Response to Missing Parts under 37 CFR 1.52 or 1.53	TURE C	OF APPLICANT, ATTORN	EY, OR AGENT
Firm Louis C. Cullman Preston Gates & Ellis, LLF Reg. No.: 39,645		Mell	
Signature	1	/	
ate 9/24/04			
CI	RTIFIC	ATE OF TRANSMISSION	N/MAILING
I hereby certify that this correspondence is b	eing facsi velope ad	mile transmitted to the USPTO or	r deposited with the United States Postal Service with tents, P.O. Box 1450, Alexandria, VA 22313-1450 on
Signature / May / O	ul	hassen	Date 9/24/09 ain a benefit by the public which is to file (and by the USPTO t

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTC process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.